Proteon Therapeutics Inc. (PRTO) Stock Price, Forecast & Analysis

USA • Nasdaq • NASDAQ:PRTO

0.8352
+0.19 (+28.45%)
At close: Jan 9, 2020
0.712
-0.12 (-14.75%)
After Hours: 1/9/2020, 8:26:19 PM

PRTO Key Statistics, Chart & Performance

Key Statistics
Market Cap18.52M
Revenue(TTM)N/A
Net Income(TTM)-18.64M
Shares22.18M
Float7.31M
52 Week High3.94
52 Week Low0.22
Yearly Dividend0
Dividend Yield0%
EPS(TTM)-0.96
PEN/A
Fwd PEN/A
Earnings (Next)N/A
IPON/A
Sector
GICS SectorN/A
GICS IndustryN/A
GICS IndustryGroupN/A
GICS SubIndustryN/A
PRTO short term performance overview.The bars show the price performance of PRTO in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 50 100 150 200

PRTO long term performance overview.The bars show the price performance of PRTO in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60

The current stock price of PRTO is 0.8352 null. In the past month the price increased by 161%. In the past year, price decreased by -66.46%.

Proteon Therapeutics Inc. / PRTO Daily stock chart

PRTO Technical Analysis

ChartMill assigns a technical rating of 7 / 10 to PRTO. When comparing the yearly performance of all stocks, PRTO is one of the better performing stocks in the market, outperforming 97.6% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

PRTO Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to PRTO. PRTO scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

PRTO Financial Highlights

Over the last trailing twelve months PRTO reported a non-GAAP Earnings per Share(EPS) of -0.9600000000000001. The EPS increased by 18.64% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -193.21%
ROE N/A
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%68%
Sales Q2Q%N/A
EPS 1Y (TTM)18.64%
Revenue 1Y (TTM)N/A

PRTO Forecast & Estimates


Analysts
Analysts73.4
Price TargetN/A
EPS Next Y32.17%
Revenue Next YearN/A

PRTO Ownership

Ownership
Inst Owners23.03%
Ins Owners31.18%
Short Float %N/A
Short RatioN/A

About PRTO

Company Profile

Proteon Therapeutics Inc. is a biopharmaceutical company. The Company is developing pharmaceuticals to address the medical needs of patients with kidney and vascular diseases. It is developing PRT-201, a recombinant human elastase, applied in a single treatment to the external surface of arteries and veins during an open surgical procedure or an endovascular intervention. Proteon Therapeutics Inc. is headquartered in Waltham, Mass.

Company Info

Proteon Therapeutics Inc.

200 WEST STREET

WALTHAM MA 02451

CEO: Timothy P. Noyes

Phone: 781-890-0102

Proteon Therapeutics Inc. / PRTO FAQ

What does Proteon Therapeutics Inc. do?

Proteon Therapeutics Inc. is a biopharmaceutical company. The Company is developing pharmaceuticals to address the medical needs of patients with kidney and vascular diseases. It is developing PRT-201, a recombinant human elastase, applied in a single treatment to the external surface of arteries and veins during an open surgical procedure or an endovascular intervention. Proteon Therapeutics Inc. is headquartered in Waltham, Mass.


What is the current price of PRTO stock?

The current stock price of PRTO is 0.8352 null. The price increased by 28.45% in the last trading session.


Does Proteon Therapeutics Inc. pay dividends?

PRTO does not pay a dividend.


What is the ChartMill technical and fundamental rating of PRTO stock?

PRTO has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 3 out of 10.


Should I buy PRTO stock?

This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on PRTO.